Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 9/20 | 0.34 |
| ▸ | PTGER3 | P43115 | 5/20 | 0.33 |
| ▸ | PTGER2 | P43116 | 5/20 | 0.33 |
| ▸ | PTGDR | Q13258 | 3/20 | 0.32 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MITF | O75030 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3043128 | 0.85 | GRM2 (0.38) | GRM2NPC1MAPTRAB9A | |
| SCHEMBL3044406 | 0.84 | MAOA (0.38) | GRM2PTGER3PTGER2 | |
| SCHEMBL3043263 | 0.83 | MAOA (0.33) | GRM2 | |
| SCHEMBL3036169 | 0.77 | MAOB (0.50) | NPC1MAPTRAB9A | |
| SCHEMBL3043205 | 0.75 | MAOA (0.38) | GRM2 | |
| SCHEMBL3041144 | 0.71 | CNR2 (0.38) | MAPT | |
| SCHEMBL3043233 | 0.71 | CNR2 (0.41) | MAPT | |
| SCHEMBL3039839 | 0.70 | ALDH1A1 (0.41) | MAPTKMT2A | |
| SCHEMBL3043443 | 0.68 | MAOA (0.43) | — | |
| SCHEMBL3045015 | 0.67 | MAOA (0.47) | GRM2NPC1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645781-B2 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | PFIZER INC (US) | 2010-01-12 | — | — | US | disclosed |
| US-20070015801-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | THOMAS RICHARD C | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015801-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | OXA1L, AADAC, MT-ND5 | GRM2 2255/4885PTGER3 4386/4885PTGER2 3462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.